KMT2C and prostate carcinoma: Our results indicate that, with the exception of breast cancer, lymphoma, head and neck cancer, kidney cancer, pheochromocytoma and paraganglioma, prostate cancer and stomach cancer, the expression level of KMT2C mRNA in tumor tissue exhibited significant alterations compared to that in normal tissue (Fig. 1A).